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Bullet point summary 
‘What is already known’ 
• Apelin is down regulated in pulmonary arterial hypertension. 
‘What this study adds’ 
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• A G protein-biased apelin peptide agonist is disease modifying in a model of PAH 
‘Clinical significance’ 
• Supports the development of G protein-biased apelin agonists for treatment of 
PAH.  
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Abstract 250 words 
Background and Purpose: Apelin is an endogenous vasodilatory and inotropic peptide 
that is down-regulated in human pulmonary arterial hypertension, however, the density 
of the apelin receptor is not significantly attenuated.  We hypothesised that a G 
protein-biased apelin analogue MM07, which is more stable than the endogenous 
apelin peptide, may be beneficial in this condition with the advantage of reduced β-
arrestin mediated receptor internalisation with chronic use. 
Experimental Approach: Male Sprague-Dawley rats received either monocrotaline to 
induce pulmonary arterial hypertension or saline and then daily intraperitoneal 
injections of either MM07 or saline for 21 days. The extent of disease was assessed 
by right ventricular catheterisation, cardiac MRI and histological analysis of the 
pulmonary vasculature. The effect of MM07 on signalling, proliferation and apoptosis 
of human pulmonary artery endothelial cells was investigated. 
Key Results: MM07 significantly reduced the elevation of right ventricular systolic 
pressure and hypertrophy induced by monocrotaline. Monocrotaline-induced changes 
in cardiac structure and function, including right ventricular end-systolic and end-
diastolic volumes, ejection fraction and left ventricular end-diastolic volume, were 
attenuated by MM07. MM07 also significantly reduced monocrotaline-induced 
muscularisation of small pulmonary blood vessels. MM07 stimulated endothelial nitric 
oxide synthase phosphorylation and expression, promoted proliferation and 
attenuated apoptosis of human pulmonary arterial endothelial cells in vitro. 
Conclusion and Implications:  Our findings suggest that chronic treatment with MM07 
is beneficial in this animal model of pulmonary arterial hypertension by addressing 
disease aetiology. These data support the development of G protein-biased apelin 
receptor agonists with improved pharmacokinetic profiles for use in human disease. 
 
Keywords: apelin, biased agonist, GPCR, pulmonary hypertension 
 
Abbreviations 
BMPR-II, bone morphogenetic protein receptor type II; CHX, cycloheximide; EBM-2, 
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endothelial basal medium 2; EGM-2,endothelial growth medium-2; FBS, foetal bovine 
serum; LV, left ventricle; MCT, monocrotaline; MRI, magnetic resonance imaging; PI, 
propidium iodide; PAECs, pulmonary artery endothelial cells; PAH, pulmonary arterial 
hypertension; PMVECs, pulmonary microvascular endothelial cells; rhVEGF, 
recombinant human vascular endothelial growth factor; RV, right ventricle, RVSP, right 
ventricular systolic pressure; TNFα, tumour necrosis factor α. 
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Introduction 
The G protein-coupled apelin receptor is emerging as a novel therapeutic target for 
pulmonary arterial hypertension (PAH) (Yang et al., 2015) with evidence of the 
beneficial effect of enhancing apelin receptor signalling in PAH supported by a small 
number of studies from PAH patients and animal models.  Expression of its 
endogenous ligand apelin is reduced in the circulation of patients with Group 1 
pulmonary hypertension, including idiopathic PAH, PAH associated with drugs or 
toxins and autoimmune disease (Goetze et al., 2006; Chandra et al., 2011).  In the 
pulmonary vasculature, pulmonary artery endothelial cells (PAECs) (Kim et al., 2013) 
and pulmonary microvascular endothelial cells (PMVECs) (Alastalo et al., 2011) from 
PAH patients express lower levels of apelin compared to cells from control donors.  
Mice lacking apelin develop more severe pulmonary hypertension under hypoxia 
(Chandra et al., 2011).  Nevertheless, the apelin receptor is still present in PAH tissue 
(Andersen et al., 2009; Kim et al., 2013, Yang et al., 2017a) and would therefore be 
available as a target for exogenous agonists to replace the missing apelin.  This 
hypothesis is substantiated by the emerging evidence that apelin may exert a range 
of protective effects in PAH.  Apelin knockout mice develop higher right ventricular 
systolic pressure (RVSP), increased muscularisation of the alveolar wall arteries and 
more loss of pulmonary microvasculature in response to hypoxia, compared to wild-
type controls (Chandra et al., 2011).  Administration of the apelin peptide (Falcão-
Pires et al., 2009; Alastalo et al., 2011) or other agents stimulating apelin expression 
(Spiekerkoetter et al., 2013; Bertero et al., 2014; Nickel et al., 2015) or downstream 
mediators of the apelin pathway (Kim et al., 2013) have demonstrated benefits in 
animal models of PAH. 
Studies to date have administered the native isoforms of the apelin peptides to animal 
models of PAH. For example, [Pyr1]apelin-13, the most predominant isoform in the 
human cardiovascular system (Maguire et al., 2009), was tested in monocrotaline 
(MCT)-induced PAH in rat (Falcão-Pires et al., 2009). As an endogenous ligand, 
[Pyr1]apelin-13 activates both G protein and β-arrestin mediated signalling of the 
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apelin receptor. Activation of the β-arrestin pathway results in receptor desensitisation 
and internalisation, leading to loss of efficacy with chronic use (Evans et al., 2001). 
Importantly, β-arrestin-mediated signalling of the apelin receptor may cause stretch-
induced myocardial hypertrophy and heart failure, whereas apelin-induced Gαi 
signalling is protective (Scimia et al., 2012). These reports suggest that minimising β-
arrestin recruitment while maintaining G protein signalling would be desirable for the 
apelin receptor.  This can be achieved by using a G protein-biased apelin receptor 
agonist. 
We have examined signalling bias of our apelin peptide analogues designed using a 
combination of computational modelling and pharmacological assays, and identified 
MM07 as a candidate for the first synthetic biased apelin receptor agonist (Brame et 
al., 2015).  The N terminal cyclised structure of MM07 (Figure 1A) was designed to 
constrain the peptide to specific conformations and protect against enzymatic 
degradation by non-specific aminopeptidases.  Molecular dynamics simulations 
showed that MM07 was expected to mimic the solution conformation of apelin-13 and 
promote a β-turn conformation at the RPRL motif, suggested to be important for initial 
recognition and binding at the apelin receptor (Macaluso and Glen 2010, Brame et al., 
2015).  MM07 was two orders of magnitude less potent than [Pyr1]apelin-13 in the 
cell-based β-arrestin and internalisation assays but was equipotent to [Pyr1]apelin-13 
in a G protein-dependent saphenous vein constriction bioassay (Brame et al., 2015).  
Based on these results, MM07 was found to be a G protein-biased apelin receptor 
agonist.  In anaesthetised rats, MM07 infusion caused a greater increase in cardiac 
output than [Pyr1]apelin-13 and an in vivo plasma half-life seven-fold longer than 
[Pyr1]apelin-13, possibly owing to the cyclisation and also to the reduced 
internalisation of MM07 bound apelin receptor (Brame et al., 2015).  In first-in-human 
experiments, MM07 was more efficacious than [Pyr1]apelin-13 at increasing forearm 
blood flow and consistent with β-arrestin bias did not exhibit loss of efficacy with 
repeated administration (Brame et al., 2015).  Additionally, both [Pyr1]apelin-13 and 
MM07 reversed an established norepinephrine constriction in human hand vein 
(Brame et al., 2015). The aim of this proof-of-concept study was to test MM07 in the 
8 
 
well-established MCT-induced model of PAH. We hypothesised that MM07 would 
effectively attenuate MCT-induced PAH development. 
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Methods and Materials 
Compliance with Requirements for Studies using Animals 
As an animal model of PAH, rat is the preferred species relative to the mouse, because 
the anatomical and functional features of rat models are more reminiscent of the 
human disease. The MCT rat model exhibits pulmonary vascular remodelling and 
raised RVSP in addition to dysfunction of airways and alveoli (Colvin and Yeager, 
2014).  MCT rats do not develop plexiform-like lesions, however changes reported in 
proximal bronchovascular structures are very similar to aspects of the human condition. 
Moreover, the MCT model remains the only animal model of PAH that has successfully 
translated a therapeutic from the laboratory to the clinic, this was bosentan, the first 
endothelin receptor antagonist. 
All rodent experiments were performed according to the local ethics committee 
(University of Cambridge Animal Welfare and Ethical Review Body), Home Office (UK) 
guidelines under the Animals (Scientific Procedures) Act 1986 Amendment 
Regulations (SI 2012/3039) and the ARRIVE guidelines (Kilkenny et al., 2010). All 
animal experiments were performed and analysed by blinded experimenters. 
Experimental Rat Model of PAH 
Attenuation of PAH pathogenesis by the apelin receptor agonist MM07 was tested in 
MCT-exposed rats using an experimental design similar to that reported by Falcão-
Pires et al., 2009 (Figure 1B). Male Sprague-Dawley rats (186±2g, Charles River 
Laboratories) were used at a relatively young age of approximately seven weeks, 
which is required for the successful induction of PAH with MCT. The power calculation 
determining the number of animals used is as follows: n>2{[(Zα+Zβ)s]/δ}2, where n is 
sample size, Zα=1.96, Zβ=1.28 for a study with 90% power and p<0.05 significance 
level, s is standard deviation, δ is minimum difference. δ is set at 20% from a sample 
with an SD of 10%, based on our previous data. The calculation gives n>5.2. The initial 
size of the MCT exposed groups were larger than the vehicle control group to account 
for possible attrition over the treatment period. 
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Rats were randomly allocated initially into two groups, the MCT group (n=16) were 
given MCT (60 mg kg-1 body weight) with the saline vehicle control group (n=12) 
receiving an equal volume of vehicle (0.9% saline) by subcutaneous injection on day 
0. From day 1 to day 20, the MCT group were further divided such that 8 rats were 
randomised to receive daily intraperitoneal (ip) injections of MM07 (1 mg kg-1 body 
weight) and 8 to receive an equal volume of vehicle (0.9% saline) daily.  Similarly, the 
vehicle control animals were randomised either to receive daily injections of MM07 (1 
mg kg-1 body weight ip, n=6) or vehicle (0.9% saline ip, n=6) resulting in 4 treatment 
groups in total (Figure 1B). The dose of MM07 was selected based on the previously 
published study that found daily injections of 200 µg kg-1 body weight of [Pyr1]apelin-
13 attenuated MCT-induced PAH, and the lower affinity and potency of MM07. 
The rats were accommodated under standard housing and husbandry conditions 
under room temperature and normoxia, in individually-ventilated cages of four rats 
each with wood chip bedding, under 12-hour light/ 12-hour dark cycle with ad libitum 
access to clean water and normal chow. The rats were monitored daily for signs of 
sickness and distress. No humane endpoint was met during the study. 
Cardiac Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) was carried out as previously described 
(Buonincontri et al., 2013) to assess cardiac performance on day 20 in a randomly 
selected sub-set of animals. The rats were anaesthetised with gaseous isoflurane for 
induction (3% in 1.5 L min-1 oxygen) and maintenance (2-2.5% in 1.5 L min-1 oxygen). 
A pressure sensor for respiration rate was used to monitor depth of anaesthesia, with 
respiration rate maintained at 45-55 breaths per minute. Body temperature was 
monitored using a rectal thermometer and maintained at 37°C using a flowing-water 
heating blanket. Prospective gating of the MRI sequences was achieved with 
electrocardiography monitoring using paediatric electrocardiography electrodes (3M 
Europe, Diegem, Belgium) on left and right forepaws. MRI was performed at 4.7 T with 
a Bruker BioSpec 47/40 system (Bruker Inc., Ettlingen, Germany). A birdcage coil of 
12cm was used for signal excitation and animals were positioned prone over a 2cm 
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surface coil for signal reception. After initial localisation images, 4-chamber and 2-
chamber views were obtained. Using these scans as a reference, short axis slices 
were acquired (FISP, TR/TE 6 ms/2.1 ms, 20-30 frames, 5 cm FOV, 256x256 matrix, 
2 mm slice thickness, bandwidth 78 kHz, flip angle 20°, NEX 3), perpendicularly to 
both the long-axis views. Full ventricular coverage in the short axis was achieved with 
no slice gap with 9-10 slices. Delineation of the LV and RV, calculation of ventricular 
volumes and ejection fraction were performed as described using Segment v1.9 
(Heiberg et al., 2010; Buonincontri et al., 2013). Owing to limitations in access to MRI 
facilities only 6 each of the MCT/saline and MCT/MM07 groups and 4 each of the 
saline and MM07 control animals were imaged, with image quality of one of the MCT 
animals sub-optimal to include in subsequent analysis. Group data for the MCT/Saline 
and MCT/MM07 groups were compared using two-tailed Student’s t-test. The rats 
were allowed to recover from anaesthesia after MRI and the intraperitoneal injection 
for day 20 was given. 
Haemodynamic Assessment by Catheterisation 
On day 21, all rats were weighed and catheterised for RV hemodynamic 
measurements as previously described (Crosby et al., 2010; Long et al., 2015). Briefly, 
rats were anaesthetised with gaseous isoflurane (3% for induction, 2-2.5% for 
maintenance, 1.5 L min-1 oxygen). Body temperature was maintained at 37°C. A 
pressure volume catheter (SPR-869, Millar) connected to the data PowerLab 16/35 
system with LabChart 5 and calibrated using the MPVS Ultra PV Unit was inserted 
into the RV via the right external jugular vein to measure RVSP as a surrogate for 
pulmonary arterial pressure. The position of the catheter was determined by the blood 
pressure and shape of the pressure-volume loops. The animal was allowed to stabilise 
for measurements. Data analysis was performed using LabChart 8 as previously 
described (Yang et al., 2017a). Group data were compared using one-way ANOVA 
with Tukey’s post-test. 
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Analysis of Cardiac and Pulmonary Vascular Morphometry 
The rats were euthanised by exsanguination, the left lung was infused with 0.8 % 
agarose to inflate, removed, fixed in 10% formalin (CellPath, Powys, UK), paraffin 
embedded and stained for smooth muscle α-actin and elastic van Gieson as described 
(Crosby et al., 2010; Long et al., 2015).  The heart was then excised, the RV was 
dissected from the LV+septum and the weight ratio of these (RV compared to 
LV+septum), also known as the Fulton index, was determined as a measure of RV 
hypertrophy.  In the left lung, small (diameter 25-75μm, 100 per section) pulmonary 
blood vessels associated with alveolar ducts were scored as completely muscular, 
partially muscular, or non-muscular. Statistical significance was assessed by 
comparing the percentage of fully muscularised vessels between groups.  The wall 
thickness of small pulmonary arterioles (20 per section) close to terminal bronchioles 
was determined by measuring the average wall thickness as a percentage of average 
lumen diameter of the vessel using ImageJ as previously described (Yang et al., 
2017a). Quantification was only performed in samples were the lungs were fully 
inflated, and fixation was optimal to preserve structure and to allow accurate 
visualisation of vascular remodelling.  Therefore data for analysis were obtained from 
a subset of animals (n=6 each for MCT/saline and MCT/MM07 groups and n=4 each 
for the saline and MM07 controls). Therefore MCT/saline and MCT/MM07 data only 
were compared using Student’s two-tailed t-test. 
Regulation of Pulmonary Arterial Endothelial Cell Signalling 
Apelin signalling is known to regulate endothelial nitric oxide synthase (eNOS), a 
critical enzyme that is thought to be protective in PAH, and AMP-activated protein 
kinase (AMPK), a regulator of energy metabolism and angiogenesis (Chandra et al., 
2011; Yang et al., 2014).  We have tested whether MM07 could modulate these two 
targets.  Human PAECs (Lonza, passages 4-5) were seeded in 96 well plates 
(Corning) in endothelial growth medium-2 (EGM-2, Lonza) with 10% foetal bovine 
serum (FBS, Gibco™ Thermoscientific), allowed to attach overnight and starved for 
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6h in endothelial basal medium 2 (EBM-2; Lonza) with 0.5% FBS to establish baseline. 
The cells were treated for 15 minutes at 37°C with PBS, [Pyr1]apelin-13 (100nM) or 
MM07 (1µM).  Phosphorylated eNOS and AMPKa were detected using a previously 
described high throughput in-cell Western assay (Nikolic et al., 2018).  The cells were 
fixed and permeabilised in cold 1% paraformaldehyde with 0.5% Triton-X for 20 
minutes, washed and blocked in PBS with 2% bovine serum albumin (BSA, Fisher 
Scientific) for 2h at room temperature.  A primary antibody against Serine-1177 
phosphorylated eNOS (Cell Signaling Technology, 1:1000 in PBS with 2% BSA, n=11 
independent experiments) or Thr-172 phosphorylated AMPKa (Cell Signaling 
Technology, 1:200 in PBS with 2% BSA, n=9 independent experiments) was applied 
for overnight incubation at 4°C.  Following PBS washes, a secondary HRP-
conjugated antibody (Cell Signaling Technology, 1:1000 in PBS with 2% BSA) was 
added for 1h incubation at room temperature.  Following washes, enhanced 
chemiluminescence (Surmodics) measurement was performed (SpectraMax L, 
Molecular Devices). 
In a set of separate experiments, human PAECs (Lonza, passages 4-5, n=9 
independent experiments) were seeded in 6-well plates (Corning) with 10% foetal 
bovine serum (FBS, Gibco™ Thermoscientific), allowed to attach overnight and 
starved for 6h in endothelial basal medium 2 (EBM-2; Lonza) with 0.5% FBS.  The 
cells were then treated for 24 hours at 37°C with PBS, [Pyr1]apelin-13 (1µM) or MM07 
(10µM).  RNA extraction was performed using a Trizol® based protocol according to 
the manufacturer’s instructions (PureLink® RNA mini kit, Life Technologies). Reverse 
transcription was performed with 500ng RNA according to the manufacturer’s 
instructions (SuperScript™ IV VILO™ master mix, Invitrogen) and quantitative real-
time PCR (qPCR) was performed for NOS3 (gene encoding eNOS) using 18S as 
internal control (AzuraView™ GreenFast qPCR Blue mix, azura genomics, 
Mastercycler Realplex2, Eppendorf). The primer sequences are: 18S Forward: 
CGGCTACCACATCCAAGGAA, Reverse:  GCTGGAATTACCGCGGCT; NOS3: 
Forward: ATGGCGAAGCGAGTGAAG, Reverse: ACTCATCCATACACAGGACCC. 
Relative expression levels were calculated using the ΔΔCt method.  Expression of 
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NOS3 mRNA was normalized to the average of the untreated control and, as is 
standard practice for qPCR data, expressed as relative fold change. Untreated control 
samples retained their individual fold change.  For qPCR experiments, a one-way 
ANOVA with Tukey’s post-test was performed to compare relative fold change 
between treatment groups. 
Regulation of Endothelial Cell Proliferation 
Apelin has been reported as a pro-proliferative and anti-apoptotic factor in endothelial 
cells (Alastalo et al., 2012, Kim et al., 2013).  We have tested if MM07 could exert 
this effect in human PAECs. To study cell proliferation, human PAECs (passages 4, 
n=6 independent experiments) were seeded at 50,000 cell per well in 8-well chamber 
slides (BD Falcon) in EGM-2 with 10%FBS, allowed to attach and then starved 
overnight in EBM-2 with 0.5% FBS to inhibit cell division.  The cells were then treated 
for 24h in EBM-2 with 2% FBS with PBS, [Pyr1]apelin-13 (1µM), MM07 (10µM) or 
recombinant human vascular endothelial growth factor (rhVEGF, 20ng/mL, R&D 
Systems) as a positive control.  The treatment media also contained 20µM 5-ethynyl-
2’-deoxyuridine (EdU, part of the Click-iT® EdU Imaging Kit, Invitrogen) as a 
nucleoside analogue incorporated in DNA as the cells replicate.  Detection of the 
incorporated EdU was carried out following the manufacturer’s instructions. The cells 
were fixed with 4% paraformaldehyde with 0.5% Triton-X for 20 minutes and stained 
with Click-iT® EdU reaction buffer containing AlexaFluor 488 azide, copper sulphate 
and Click-iT® EdU buffer additive for 30 minutes at room temperature.  The chambers 
were mounted in DAPI Vectashield medium (Vectorlabs) and imaged for blue and 
green fluorescence on an Olympus BX63 microscope with an EXi Blue camera 
(QImaging) using the cellSens software (v1.14, Oylmpus).  For each cell chamber, 
images were taken at 10x magnification for 5 random fields based on blue DAPI 
fluorescence. Counting of DAPI and EdU positive cells were performed using the 
cellSens software with a cell area threshold to exclude cell debris and doublets applied 
to all images.  The amount of cell proliferation was measured as the percentage of 
EdU positive cells to DAPI positive cells. 
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Rescue of Endothelial Cell Apoptosis 
The effects of MM07 on endothelial cell apoptosis was tested and compared with 
rhVEGF using human PAECs (Lonza, passages 4-6, n=3 donors with 3 independent 
experiments each) as previously described (Long et al., 2015) following protocol 
optimisation in donor lines 1-3.  Briefly, PAECs were seeded in six-well tissue culture 
plates at 200,000 cells/well in EGM-2 with 10% FBS and allowed to attach.  On the 
next day, wells were washed with PBS and the media changed to either EBM-2 with 
2% FBS or 10% FBS controls. MM07 (10µM) or rhVEGF (10ng/mL) were added to the 
wells and incubated for 18 hours. Apoptosis was induced by incubating the cells with 
tumour necrosis factor α (TNFα; R&D Systems, 1.5ng/mL) and cycloheximide (CHX; 
Sigma, 20µg/ml) for 5 hours in the experimental wells. Control wells did not receive 
TNFα and CHX treatment.  Cells were then washed in PBS, trypsinised (Lonza), 
transferred into binding buffer for the apoptosis assay (Thermoscientific) and stained 
with anti-annexin FITC-conjugated antibody (1:2 stock dilution) and propidium iodide 
(PI, 20µg/mL) for 15 minutes at room temperature.  Cells were filtered through 50µM 
filters (Sysmex Partec) and kept on ice before flow cytometry (CantoII). For each 
condition 10,000 events were recorded.  Data analysis was performed on FlowJo v10 
(FlowJo LLC, Oregon, US).  Annexin+/PI+ cells were classified as ‘dead’, Annexin+/PI- 
cells ‘apoptotic’ and Annexin-/PI- as ‘healthy’.  Gates were adjusted such that 
approximately equal numbers of ‘healthy’ and ‘apoptotic’ cells occurred in the 
TNFα/CHX treated group as this provided a large window for either further induction 
or rescue of apoptosis. The raw percentage of cells in each gate were used in the data 
analysis. For statistical analysis, technical replicates were excluded if the apoptotic 
induction was less than 5%. The average induction of apoptosis of the analysed 
experiments was 19.53±1.76%. 
Data and Statistical Analysis 
Data and statistical analysis comply with the recommendations on experimental 
design and analysis in pharmacology.  Data are expressed as mean±SEM.  
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Statistical analyses were conducted in GraphPad Prism 6.  Post hoc tests were done 
only if F was significant and there was no variance in homogeneity.  The number of 
animals in each group included for statistical tests is shown in the figure legend for 
that analysis.  For the human PAEC assays except qPCR, as some variability in the 
basal amount of eNOS phosphorylation, cell proliferation and apoptotic induction was 
observed, as illustrated by the example of variable amounts of basal apoptotic 
response (Supplementary Figure 1).  To minimise the confounding variability 
between independent experiments, a repeated measures one-way ANOVA with 
Dunnett’s post-test was performed to compared treated groups with PBS-treated 
control group. For all experiments P≤0.05 was considered statistically significant.  
Materials 
All chemical reagents were purchased from Sigma (Poole, UK), unless otherwise 
stated.  Human [Pyr1]apelin-13 and MM07 were synthesised by Severn Biotech 
(Kidderminster, UK) to GLP standard using Fmoc chemistry on a solid phase support 
matrix to 98% purity by Maldi-TOF mass spectroscopy and HPLC analysis.  Peptides 
were tested for sterility and demonstrated to be pyrogen free and biological activity 
was confirmed using a β-arrestin recruitment assay (DiscoverX, Fremont, USA) as 
described (Yang et al., 2017a). 
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Results 
Cardioprotective Effects of MM07 Shown by Cardiac MRI 
On day 20, changes in the appearance and motion of ventricles were detectable by 
non-invasive cardiac MRI, as shown in the snapshots of the heart of representative 
animals in the short (Figure 2A) and long (Figure 2B) axis views and in the videos 
(Videos 1-6).  Compared to the saline-injected control rats, MCT-exposed rats 
developed an enlarged RV.  At the end of systole, MCT-exposed rats had more 
residual volume in the RV compared to the controls.  In early diastole, MCT exposure 
resulted in a distortion in the interventricular septal wall.  The filling of the LV and RV 
appeared to be less synchronous in the MCT-exposed animals and the LV appeared 
to be insufficiently filled at the end of diastole.  Administration of MM07 to MCT-
exposed rats attenuated these structural changes, as their heart appeared to be 
intermediate between MCT and saline control animals.  Additionally, MM07 alone did 
not appear to alter cardiac structure and function compared to the saline controls. 
Quantitative analysis of the cardiac MRI revealed that MCT exposure resulted in an 
increase in RV end-diastolic and end-systolic volumes (Figure 3A-B), indicating an 
enlarged RV that could not contract to empty sufficiently.  The compound effect of 
these was a reduced RV ejection fraction compared to the saline-injected control rats 
(Figure 3C).  MCT exposure also caused LV under-filling as a consequence of 
reduced LV end-diastolic volume (Figure 3D), without altering LV end-systolic volume 
and ejection fraction (Figure 3E-F).  MM07 treatment significantly attenuated MCT-
induced changes in RV end-diastolic and end-systolic volumes, ejection fraction and 
LV end-diastolic volume.  In the rats not exposed to MCT, all measured parameters 
with MM07 alone were comparable to the saline controls (Figure 3A-F). 
MM07 Attenuated the Development of PAH in Monocrotaline Exposed 
Rats 
Next, invasive haemodynamic measurements were carried out in isoflurane-
anaesthetised rats.  Compared to the saline-injected rats, RVSP was significantly 
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elevated in MCT-exposed rats (Figure 4A) (Table 1), indicating that these animals have 
developed pulmonary hypertension as expected.  Compared to this group, RVSP 
was significantly lower in MCT-exposed rats treated with MM07, to a level that is higher 
than but not statistically different from the saline-injected controls.  MM07 injection 
alone did not alter RVSP compared to the vehicle-injected group. 
MM07 Attenuated Monocrotaline-Induced Right Ventricular Hypertrophy 
After the animals were sacrificed, structural changes in heart ventricles were assessed.  
Compared to the controls, the Fulton index were significantly increased in in MCT-
exposed rats, indicating the development of RV hypertrophy (Figure 4B) (Table 1).  
This structural change of the RV was significantly attenuated by MM07 administration.  
However, MM07 did not completely abolish the development of RV hypertrophy 
resulting from MCT.  MM07 injection alone did not alter the Fulton index compared to 
the saline controls. 
MM07 Attenuated Monocrotaline-Induced Pulmonary Vascular Remodelling 
In order to determine the effect of MM07 on the pathogenesis of PAH, morphometry 
of pulmonary arterioles was examined and the extent of vascular remodelling was 
scored.  Representative photomicrographs of rat lung sections with smooth muscle 
actin and van Giesen’s staining are shown in Figure 5.  As expected, MCT injection 
increased the percentage of fully muscularised small vessels (Figure 6A) and the wall 
thickness of small to medium-sized arterioles (Figure 6B) (Table 1).  MCT-induced 
vascular remodelling was attenuated by MM07 administration, as the proportion of 
fully muscularised small vessels and the arteriolar wall thickness were significantly 
reduced.  The extent of small vessel muscularisation and arteriolar wall thickness 
was similar in saline and MM07-injected control groups. 
MM07 Activates Endothelial Nitric Oxide Synthase and AMP-Activated 
Protein Kinase 
In order to investigate the potential mechanisms underlying the benefit of MM07 in 
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MCT-induced PAH, we have tested the effect of MM07 on protective signalling in 
PAECs known to be activated by apelin signalling.  Knockdown of apelin expression 
reduces the phosphorylation and activation of eNOS and AMPK in PAECs (Chandra 
et al., 2011).  Human PAECs were stimulated acutely with [Pyr1]apelin-13 or MM07.  
Both ligands significantly increased phosphorylation of eNOS (Figure 7A) and AMPKa 
(Figure 7B), compared to control cells.  Stimulation of PAECs with [Pyr1]apelin-13 or 
MM07 also increased the mRNA levels of eNOS (NOS3 gene) (Figure 7C). 
MM07 Promoted Proliferation of Pulmonary Arterial Endothelial Cells 
Next, we examined the functional effect of MM07 on endothelial cell homeostasis.  
Previous studies have shown that apelin induced proliferation of PAECs and PMVECs 
(Alastalo et al., 2011, Kim et al., 2013).  We have stimulated human PAECs with 
ligands and measured cell proliferation using a DNA replication-based assay.  
Significantly more EdU incorporation was induced by the positive control treatment, 
rhVEGF, compared to untreated controls.  Similarly, both [Pyr1]apelin-13 and MM07 
significantly resulted in significantly higher proportion of proliferating cells (Figure 8A 
for representative images and 8B for inter-group comparisons). 
MM07 Exerted Anti-Apoptotic Effects on Pulmonary Arterial Endothelial 
Cells 
Apelin has been reported to have anti-apoptotic roles on endothelial cells in the 
pulmonary circulation (Alastalo et al., 2011; Kim et al., 2013).  The effect of MM07 on 
apoptosis of primary human PAECs was investigated using donor cell lines.  
Treatment with TNFα/CHX resulted in a significant increase in Annexin+/PI- staining 
(19.5%).  rhVEGF pre-treatment for 18 hours significantly attenuated this apoptotic 
induction (11.6%) as did MM07 (4.5%) (Figure 9).  In control experiments, EBM-2 2% 
FBS control (serum and growth factor starved) was compared to a healthy control 
(EGM-2 10% FBS) and the extent of rhVEGF and MM07 rescue on serum and growth 
factor starvation assessed.  Serum and growth factor starvation resulted in a 
significant induction of Annexin+/PI- staining (9.3%) which was almost wholly rescued 
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by 18 hours of rhVEGF pre-treatment (8.9%).  However, MM07 displayed no rescue 
from serum and growth factor starvation (Supplementary Figure 2). 
  
21 
 
Discussion and Conclusions 
This is the first study of an apelin receptor biased agonist in an animal model of 
disease.  Our results showed that MM07 attenuated the elevation of RVSP, RV 
hypertrophy, cardiac dysfunction and pulmonary vascular remodelling induced by MCT.  
MM07 also conferred pro-proliferative and anti-apoptotic effects on human PAECs in 
vitro.  Our findings suggest that G protein-biased agonism of the apelin receptor has 
potential beneficial effects in PAH, indicating that the apelin receptor is a therapeutic 
target tractable to biased agonism. 
The goal of supplying exogenous apelin receptor agonist in PAH is to replace the 
missing endogenous peptide.  The reduction in apelin expression has been shown to 
result from the dysfunction of bone morphogenetic protein receptor type II (BMPR-II) 
(Alastalo et al., 2011) which is the most frequently mutated gene in familial and 
sporadic PAH (Machado et al., 2015) and a critical component in a pathway central to 
PAH pathogenesis (Morrell et al., 2015).  It has been reported that apelin is a 
transcriptional target of BMPR-II, mediated by the miR-130/301 family and PPARγ in 
pulmonary vascular endothelial cells (Alastalo et al., 2011; Bertero et al., 2014).  
Furthermore, apelin expression in the RV is decreased in the MCT (Falcão-Pires et al., 
2009) and Sugen 5416+hypoxia-induced (Drake et al., 2011; Frump et al., 2015) rat 
models of PAH.  Importantly, apelin levels are found to be correlated with contractile 
and diastolic function of the RV in the Sugen+hypoxia model (Neto-Neves et al., 2017). 
Interestingly, elabela/toddler, the second endogenous ligand of the apelin receptor 
encoded by APELA gene, is also reduced in cardiopulmonary tissues from PAH 
patients and animal models (Yang et al., 2017a).  In an early study of particular 
interest, the apelin peptide was tested in MCT-induced PAH (Falcão-Pires et al., 2009). 
The apelin signalling pathway is also implicated in pulmonary veno-occlusive disease 
(Lathen et al., 2014) and chronic thromboembolic pulmonary hypertension (Miao et al., 
2017).  As expected, agents that activate apelin expression or act as downstream 
effectors of apelin signalling have demonstrated beneficial effects in PAH animal 
models (Kim et al., 2013; Spiekerkoetter et al., 2013; Bertero et al., 2014; Nickel et al., 
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2015). 
One caveat may limit the therapeutic efficacy and clinical development of native apelin 
peptides.  As a G protein-coupled receptor, the ligand-activated apelin receptor is 
phosphorylated by G protein-coupled receptor kinases and β-arrestin is recruited to 
the receptor.  This switches off G protein-mediated signalling, triggers receptor 
desensitisation, internalisation and removal of the bound apelin ligand, leading to loss 
of efficacy with chronic administration of the peptide (Evans et al., 2001; Violin and 
Lefkowitz 2007; Rajagopal et al., 2010).  Importantly, β-arrestin-mediated signalling 
is also involved in an apelin-independent stretch-sensitive function of the apelin 
receptor and may cause myocardial hypertrophy and heart failure, whereas apelin-
induced Gαi signalling is protective (Scimia et al., 2012).  This need to selectively or 
preferentially activate a subset of downstream signalling pathways forms the rationale 
to investigate signalling bias and develop G protein-biased agonists of the apelin 
receptor.  Using a number of in vitro screening assays, our lab have discovered 
MM07, the first apelin analogue peptide acting as a G protein-biased agonist of the 
apelin receptor (Brame et al., 2015). 
Having demonstrated the activity of MM07 in vivo under normal physiological 
conditions (Brame et al., 2015), we tested this peptide, or more generally the concept 
of G protein-biased agonism of the apelin receptor, in a disease model.  The current 
study used an experimental design with the same dose of MCT and time course as 
Falcão-Pires et al., 2009, in order to verify if MM07 could attenuate the development 
of PAH.  In this previous three-week experiment, rats injected with 60mgkg-1 MCT 
were treated with intraperitoneal injections of the predominant endogenous apelin 
peptide, [Pyr1]apelin-13, at a dose of 200μgkg-1 per day.  The authors reported that 
[Pyr1]apelin-13 ameliorated the elevation in RVSP and development of RV hypertrophy, 
but failed to attenuate the thickening of pulmonary arterioles (Falcão-Pires et al., 2009).  
Owing to the lower receptor binding affinity and potency of MM07 compared to 
[Pyr1]apelin-13 (Brame et al., 2015), a higher dose of MM07 (1mgkg-1 per day) was 
used compared to the previous study with [Pyr1]apelin-13 (200μgkg-1 per day in 
Falcão-Pires et al., 2009). 
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The cardiac MRI showed that MCT caused an enlargement of the RV and systolic 
dysfunction, indicating the RV failed to match the increased afterload due to increased 
pulmonary vascular resistance, consistent with previous reports (Porvasnik et al., 2010, 
Redout et al., 2010).  The combined effect of a lowered RV output, compression of 
the LV due to RV enlargement and the leftward septal displacement led to under filling 
of the LV, as shown by the reduced LV volume at end-diastole (Gan et al., 2006).  
Importantly, MM07 attenuated the detrimental effects of MCT by limiting the 
enlargement of the RV and improving its ejective function which in turn alleviated 
under-filling of the LV.  In healthy control animals, MM07 did not significantly alter any 
of these parameters, suggesting that its actions can only be revealed upon injury with 
MCT and does not affect the normal physiological function.  Previous studies have 
proposed possible explanations for the observed benefits of MM07.  Apelin receptor 
signalling is known to increase cardiac contractility and output (Szokodi et al., 2002; 
Maguire et al., 2009; Brame et al., 2015), possibly by activating myosin light chain 
kinase to increase myofilament calcium sensitivity (Perjés et al., 2014) and by a 
positive lusitropic effect (Peyronnet et al., 2017), so the enhanced cardiac 
performance does not require an increase in oxygen consumption (Charo et al., 2009).  
MM07-induced haemodynamic improvement was confirmed by invasive right heart 
catheterisation.  MM07-injected rats were shown to have significantly lower RVSP in 
response to MCT exposure compared to those not treated with MM07.  This is 
unlikely to be caused by an acute vasodilatory effect of MM07, as the compound was 
not injected on the day of catheterisation.  In agreement, chronic administration of the 
native apelin peptide has been reported to reduce RVSP in mouse and rat models of 
PAH (Falcão-Pires et al., 2009; Alastalo et al., 2011).  Importantly, MCT-induced RV 
hypertrophy was less pronounced in MM07-treated rats, consistent with the previous 
study showing that apelin receptor ligand-activated Gαi protein signalling protected 
against cardiac hypertrophy and failure (Scimia et al., 2012).  Taken together, our 
physiological results have demonstrated a protective of MM07 against MCT- induced 
cardiac dysfunction. 
While the signalling pathways activated by the apelin receptor are not fully 
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characterized, previous studies have shown that eNOS expression and 
phosphorylation is reduced with apelin knockdown and in apelin knockout animals 
(Chandra, et al., 2011), but eNOS phosphorylation can be induced by [Pyr1]apelin-13 
and elabela/toddler (Yang et al., 2017a).  We have found that MM07 could also 
induce eNOS phosphorylation acutely and then increase eNOS expression in human 
PAECs.  The important role of eNOS is demonstrated by the increased susceptibility 
to hypoxia-induced pulmonary hypertension in eNOS deficient mice (Fagan et al., 
1999) and by the therapeutic benefit of eNOS gene transfer in MCT-exposed rats 
(Zhao et al., 2006).  Importantly, eNOS functions beyond generating a vasodilator, as 
eNOS gene transfer restored the microvascular loss in the MCT model (Zhao et al., 
2006).  AMPK has been reported to mediate the pro-angiogenic effects of apelin and 
activation of AMPK has beneficial effect in PAH animal models (Chandra, et al., 2011; 
Yang et al., 2014).  We have found that MM07 could increase the phosphorylation of 
AMPKa in endothelial cells.  There are other potential mechanisms for the beneficial 
effects of MM07, it is clear that apelin receptor signalling regulates multiple effector 
pathways and cell types in the pulmonary vasculature.  For example, apelin was 
reported to induce the endothelial ATPase CD39 and limit the emergence of apoptosis-
resistant PAECs (Helenius et al., 2015), possibly at a later stage of PAH pathogenesis.  
Moreover, it has been reported that apelin regulates myocyte enhancer factor 2, which 
in turn activates miR-424/miR-503 and genes contributing to endothelial homeostasis.  
This axis also inhibits the expression of fibroblast growth factor 2 and its receptor and 
thus exerts anti-proliferative effects on pulmonary arterial smooth muscle cells 
(Alastalo et al., 2011; Kim et al., 2013; Helenius et al., 2015; Kim et al., 2015).  Further 
experiments, possibly using a co-culture system, are required to understand how G 
protein-biased apelin signalling in endothelial cell may impact the homeostasis of 
smooth muscle cells. 
It has been suggested that the benefits of apelin may extend beyond its acute 
vasodilatory and positive inotropic activities, as apelin regulates the homeostasis of 
pulmonary vascular cells.  Conversely, deficiency of apelin may contribute to the 
imbalance between proliferation and apoptosis of these cells, leading to pathological 
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vascular remodelling, which is the ultimate cause of PAH (Andersen et al., 2011; Yang 
et al., 2015).  In the current study, MM07 demonstrated disease modification as it 
attenuated pulmonary vascular remodelling in terms of arteriolar muscularisation and 
wall thickening, thereby mitigating the key driving feature in the pathogenesis of PAH 
(Rabinovitch 2012; Morrell et al., 2016).  Endothelial apoptosis is thought to initiate 
PAH and contribute to the loss of microvasculature in human disease and animal 
models (Wilson et al., 1992; Rabinovitch 2012).  In this study, we have investigated 
the effect of MM07 on the homeostasis of PAECs, in order to understand the 
mechanism underlying its protective effects on vascular remodelling.  Apelin has 
been reported to promote survival of pulmonary vascular endothelial cells (Alastalo et 
al., 2011; Kim et al., 2013).  We used an EdU incorporation assay to measure cell 
proliferation, which has the advantage of not being confounded by the metabolic state 
of the cell, as it measures DNA synthesis directly.  We found that MM07 promoted 
PAEC proliferation in 24h, as did [Pyr1]apelin-13.  To test the ability of MM07 to rescue 
endothelial apoptosis, we utilised a previously published apoptosis assay using 
TNFα/CHX to induce apoptosis in healthy human PAECs (Long et al., 2015).  Under 
usual conditions TNFα prevents apoptosis of endothelial cells through activation of the 
NF-κB pathway, however, in conditions of global protein synthesis suppression, such 
as produced by concurrent application of CHX, apoptosis is induced through TNF-R1 
leading to JNK phosphorylation.  In our experiments, MM07, reduced apoptosis of 
healthy human PAECs induced by TNFα/CHX, demonstrating prevention of 
endothelial damage in vitro.  Interestingly, MM07 did not rescue endothelial damage 
caused by growth factor and serum starvation, a less severe treatment than 
TNFα/CHX, suggesting it may be more suitable in early disease where high levels of 
endothelial damage are thought to be critical drivers of disease development.  We 
acknowledge that PMVECs may be more reminiscent of endothelium from the small 
pulmonary vessels than PAECs.  However, the pro-proliferative and anti-apoptotic 
effect of native apelin peptide have been reported in both normal PAECs and PMVECs 
(Alastalo et al., 2011; Kim et al., 2013), and even in endothelial cells from other 
vascular beds or organisms (summarised in Pitkin et al., 2011).  Overall, our finding 
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provides a mechanism and supports apelin mimetics as important in treating disease 
aetiology itself rather than simply relying on vasodilatation, as is the case with current 
therapeutics. 
Recent studies have generated more insight on the apelin receptor structure (Ma et 
al., 2017), apelin degradative pathways (Murza et al., 2014; McKinnie et al., 2016; 
Yang et al., 2017b), antagonists (Le Gonidec et al., 2017) and more peptide biased 
agonists of the apelin receptor (Ceraudo et al., 2014; McAnally et al., 2017; Murza et 
al., 2017), providing new tools to further investigate biased agonism of the apelin 
receptor.  One pharmacokinetic property that distinguishes MM07 from [Pyr1]apelin-
13 is stability.  Although still relatively short at under 20 minutes, MM07 has a 
significantly longer in vivo plasma half-life than [Pyr1]apelin-13 (Brame et al., 2015), 
which may be a consequence of its N terminal cyclisation and/or reduced removal due 
to receptor internalisation.  This may have enabled MM07 to produce greater target 
cover compared to [Pyr1]apelin-13 with each daily injection. Our previous human study 
has shown that the magnitude of vascular response drops with repeated dosing of 
[Pyr1]apelin-13 owing to receptor desensitisation, but not with MM07 (Brame et al., 
2015).  This phenomenon may also contribute to the benefit of MM07 observed in the 
current chronic study.  Building on the efficacy of MM07, novel biased apelin receptor 
agonists with higher binding affinity, higher potency in G protein signalling, more G 
protein bias and even better stability, such as the small molecule CMF-019 (Read et 
al., 2016), could be tested in PAH animal models in future studies.  As G protein-
biased agonism of the apelin receptor was shown to be safe in chronic use, further 
studies may be able to reduce the number of animals in the agonist-only control group. 
This study has demonstrated that a G protein-biased agonist of the apelin receptor 
could attenuate the development of MCT-induced PAH, which is an acute model of 
moderate severity.  In future studies, this concept could be validated in the 
Sugen5416 and chronic hypoxia-induced model of PAH which exhibits more severe 
pulmonary vascular remodelling (Stenmark et al., 2009).  More importantly what is 
required to corroborate the data we have obtained with MM07 in the MCT prevention 
model is testing of an apelin G protein-biased agonist in a more clinically relevant 
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reversal model of PAH.  This may require the development of apelin agonists with 
improved pharmacokinetic properties to allow maintained target exposure from once 
a day administration beyond that which is likely achieved with the relatively short lived 
peptide MM07. 
In conclusion, this proof-of-principle study demonstrated the effectiveness of MM07, a 
G protein-biased agonist of the apelin receptor, in attenuating the development of 
MCT-induced PAH.  In addition to reducing the elevation of RVSP and hypertrophy 
as previously shown with [Pyr1]apelin-13, MM07 also attenuated functional changes 
of the heart and vascular remodelling in the lung.  At the cellular level, MM07 acts as 
a pro-proliferative and anti-apoptotic factor that activates beneficial signalling in 
endothelial cells.  By selectively activating downstream pathways, biased agonists 
have been shown to be equally effective as the native unbiased agonist with extra 
benefits owing to the differential signalling. This is illustrated by the G protein-biased 
agonists of the μ-opioid receptor, TRV130 and PZM21, which produced greater pain 
relief than morphine with reduced β arrestin-mediated respiratory depression (Manglik 
et al., 2016; Viscusi et al., 2016).  The results from the current study suggest that 
biased agonism may also be exploited in the treatment of PAH. 
 
  
28 
 
References 
Alastalo TP, Li M, Perez Vde J, Pham D, Sawada H, Wang JK et al (2011). 
Disruption of PPAR gamma/beta-catenin-mediated regulation of apelin impairs 
BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest 
121:3735-3746. 
Andersen CU, Markvardsen LH, Hilberg O, Simonsen U (2009). Pulmonary 
apelin levels and effects in rats with hypoxic pulmonary hypertension. Respir Med 
103:1663-1671. 
Andersen CU, Hilberg O, Mellemkjaer S, Nielsen-Kudsk JE, Simonsen U (2011). 
Apelin and pulmonary hypertension. Pulm Circ 1:334-346. 
Bertero T, Lu Y, Annis S, Hale A, Bhat B, Saggar R et al (2014). Systems-level 
regulation of microRNA networks by miR-130/301 promotes pulmonary 
hypertension. J Clin Invest 124:3514-3528. 
Brame AL, Maguire JJ, Yang P, Dyson A, Torella R, Cheriyan J et al (2015). 
Design, characterization, and first-in-human study of the vascular actions of a 
novel biased apelin receptor agonist. Hypertension 65:834-840. 
Buonincontri G, Methner C, Carpenter TA, Hawkes RC, Sawiak SJ, Krieg T 
(2013). MRI and PET in mouse models of myocardial infarction. J Vis Exp 
2013:e50806. 
Ceraudo E, Galanth C, Carpentier E, Banegas-Font I, Schonegge AM, Alvear-
Perez R et al (2014) Biased signalling favoring Gi over beta-arrestin promoted by 
an apelin fragment lacking the C-terminal phenylalanine. J Biol Chem 289:24599-
24610. 
Chandra SM, Razavi H, Kim J, Agrawal R, Kundu RK, de Jesus Perez V et al 
(2011). Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary 
hypertension. Arterioscler Thromb Vasc Biol 31:814-820. 
Charo DN, Ho M, Fajardo G, Kawana M, Kundu RK, Sheikh AY et al (2009). 
Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol 
29 
 
Heart Circ Physiol 297: H1904-H1913. 
Colvin KL, Yeager ME (2014).  Animal models of pulmonary hypertension: 
Matching disease mechanisms to etiology of the human disease.  J Pulm Respir 
Med 4:198. 
Crosby A, Jones FM, Southwood M, Stewart S, Schermuly R, Butrous G et al 
(2010). Pulmonary vascular remodelling correlates with lung eggs and cytokines 
in murine schistosomiasis. Am J Respir Crit Care Med 181:279-288. 
Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y et al (2011).  Molecular 
signature of a right heart failure program in chronic severe pulmonary 
hypertension. Am J Respir Cell Mol Biol 45:1239-1247. 
Evans NA, Groarke DA, Warrack J, Greenwood CJ, Dodgson K, Milligan G et al 
(2001). Visualizing differences in ligand-induced beta-arrestin-GFP interactions 
and trafficking between three recently characterized G protein-coupled receptors. 
J Neurochem 77:476-485. 
Fagan KA, Fouty BW, Tyler RC, Morris KG Jr, Hepler LK, Sato K et al (1999). 
The pulmonary circulation of homozygous or heterozygous eNOS-null mice is 
hyperresponsive to mild hypoxia. J Clin Invest 103:291–299 
Falcão-Pires I, Goncalves N, Henriques-Coelho T, Moreira-Goncalves D, 
Roncon-Albuquerque R Jr, Leite-Moreira AF (2009). Apelin decreases myocardial 
injury and improves right ventricular function in monocrotaline-induced pulmonary 
hypertension. Am J Physiol Heart Circ Physiol 296:H2007-2014. 
Frump AL, Goss KN, Vayl A, Albrecht M, Fisher A, Tursunova R et al (2015). 
Estradiol improves right ventricular function in rats with severe angioproliferative 
pulmonary hypertension: effects of endogenous and exogenous sex hormones. 
Am J Physiol Lung Cell Mol Physiol 308:L873-390. 
Gan C, Lankhaar JW, Marcus JT, Westerhof N, Marques KM, Bronzwaer JG et al 
(2006). Impaired left ventricular filling due to right-to-left ventricular interaction in 
patients with pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 
290:H1528-1533. 
30 
 
Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S et al 
(2006) Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept 
133:134-138. 
Heiberg E, Sjogren J, Ugander M, Carlsson M, Engblom H, Arheden H (2010). 
Design and validation of Segment--freely available software for cardiovascular 
image analysis. BMC Med Imaging 10:1. 
Helenius MH, Vattulainen S, Orcholski M, Aho J, Komulainen A, Taimen P et al 
(2015). Suppression of endothelial CD39/ENTPD1 is associated with pulmonary 
vascular remodelling in pulmonary arterial hypertension. Am J Physiol Lung Cell 
Mol Physiol 308:L1046-1057. 
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010). Improving 
Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal 
Research. PLoS Biol 8(6): e1000412. 
Kim J, Kang Y, Kojima Y, Lighthouse JK, Hu X, Aldred MA et al (2013). An 
endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in 
pulmonary arterial hypertension. Nat Med 19:74-82. 
Kim J, Hwangbo C, Hu X, Kang Y, Papangeli I, Mehrotra D et al (2015). 
Restoration of impaired endothelial myocyte enhancer factor 2 function rescues 
pulmonary arterial hypertension. Circulation 131:190-199 
Lathen C, Zhang Y, Chow J, Singh M, Lin G, Nigam V (2014). ERG-APLNR axis 
controls pulmonary venule endothelial proliferation in pulmonary veno-occlusive 
disease. Circulation 130:1179-1191. 
Le Gonidec S, Chaves-Almagro C, Bai Y, Kang HJ, Smith A, Wanecq E (2017).  
Protamine is an antagonist of apelin receptor, and its activity is reversed by 
heparin. FASEB J 31:2507-2519. 
Long L, Ormiston ML, Yang X, Southwood M, Graf S, Machado RD et al (2015). 
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary 
arterial hypertension. Nat Med 21:777-785. 
31 
 
Ma Y, Yue Y, Ma Y, Zhang Q, Zhou Q, Song Y et al (2017). Structural basis for 
apelin control of the human apelin receptor. Structure 25:858-866. 
Macaluso NJ, Glen RC (2010). Exploring the 'RPRL' motif of apelin-13 through 
molecular simulation and biological evaluation of cyclic peptide analogues. 
ChemMedChem 5:1247-1253. 
Machado RD, Southgate L, Eichstaedt CA, Aldred MA, Austin ED, Best DH et al 
(2015). Pulmonary arterial hypertension: a current perspective on established 
and emerging molecular genetic defects. Hum Mutat 36:1113-27. 
Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP (2009). [Pyr1]apelin-13 identified 
as the predominant apelin isoform in the human heart: vasoactive mechanisms 
and inotropic action in disease. Hypertension 54:598-604. 
Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G et al (2016). 
Structure-based discovery of opioid analgesics with reduced side effects. Nature 
537:185-190. 
Masri B, Lahlou H, Mazarguil H, Knibiehler B, Audigier Y (2002). Apelin (65-77) 
activates extracellular signal-regulated kinases via a PTX-sensitive G protein. 
Biochem Biophys Res Commun 290:539-545. 
McAnally D, Siddiquee K, Sharir H, Qi F, Phatak S, Li JL et al (2017). A 
Systematic Approach to Identify Biased Agonists of the Apelin Receptor through 
High-Throughput Screening. SLAS Discov 22:867-878. 
McKinnie SM, Fischer C, Tran KM, Wang W, Mosquera F, Oudit et al (2016). The 
Metalloprotease Neprilysin Degrades and Inactivates Apelin Peptides. 
Chembiochem 17:1495-1498. 
Miao R, Wang Y, Wan J, Leng D, Gong J, Li J et al (2017). Microarray analysis 
and detection of microRNAs associated with chronic thromboembolic pulmonary 
hypertension. Biomed Res Int 2017:8529796. 
Morrell NW, Bloch DB, ten Dijke P, Goumans MJ, Hata A, Smith J et al (2016). 
Targeting BMP signalling in cardiovascular disease and anaemia. Nat Rev 
32 
 
Cardiol 13:106-120. 
Murza A, Belleville K, Longpre JM, Sarret P, Marsault E (2014). Stability and 
degradation patterns of chemically modified analogs of apelin-13 in plasma and 
cerebrospinal fluid. Biopolymers 102:297-303. 
Murza A, Sainsily X, Côté J, Bruneau-Cossette L, Besserer-Offroy É, Longpré JM 
et al (2017). Structure-activity relationship of novel macrocyclic biased apelin 
receptor agonists. Org Biomol Chem 15:449-458. 
Neto-Neves EM, Frump AL, Vayl A, Kline JA, Lahm T (2017). Isolated heart 
model demonstrates evidence of contractile and diastolic dysfunction in right 
ventricles from rats with sugen/hypoxia-induced pulmonary hypertension. Physiol 
Rep 5: e13438 
Nickel NP, Spiekerkoetter E, Gu M, Li CG, Li H, Kaschwich M et al (2015). Elafin 
reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic 
protein signaling. Am J Respir Crit Care Med 191:1273-1286. 
Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage SD, Dinter T et al 
(2018). Bone Morphogenetic Protein 9 is a Mechanistic Biomarker of 
Portopulmonary Hypertension. Am J Respir Crit Care Med in press. 
Perjes A, Skoumal R, Tenhunen O, Konyi A, Simon M, Horvath IG et al (2014). 
Apelin increases cardiac contractility via protein kinase Cepsilon- and 
extracellular signal-regulated kinase-dependent mechanisms. PloS one 
9:e93473. 
Peyronnet R, Bollensdorff C, Capel RA, Rog-Zielinska EA, Woods CE, Charo DN 
et al (2017). Load-dependent effects of apelin on murine cardiomyocytes. Prog 
Biophys Mol Biol 130:333-343. 
Pitkin SL, Maguire JJ, Bonner TI, Davenport AP (2011). International Union of 
Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, 
distribution, pharmacology, and function. Pharmacol Rev 62:331-342. 
Porvasnik SL, Germain S, Embury J, Gannon KS, Jacques V, Murray J et al 
33 
 
(2010). PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, 
reduces monocrotaline-induced pulmonary arterial hypertension and right 
ventricular hypertrophy in rats. J Pharmacol Exp Ther 334:364-372 
Rabinovitch M (2012). Molecular pathogenesis of pulmonary arterial 
hypertension. J Clin Invest 122:4306-4313. 
Rajagopal S, Rajagopal K, Lefkowitz RJ (2010). Teaching old receptors new 
tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9:373-386. 
Read C, Fitzpatrick CM, Yang P, Kuc RE, Maguire JJ, Glen RC et al (2016). 
Cardiac action of the first G protein biased small molecule apelin agonist. 
Biochem Pharmacol 116:63-72. 
Redout EM, van der Toorn A, Zuidwijk MJ, van de Kolk CW, van Echteld CJ, 
Musters RJ et al (2010). Antioxidant treatment attenuates pulmonary arterial 
hypertension-induced heart failure. Am J Physiol Heart Circ Physiol 298:H1038-
1047. 
Scimia MC, Hurtado C, Ray S, Metzler S, Wei K, Wang J et al (2012). APJ acts 
as a dual receptor in cardiac hypertrophy. Nature 488:394-398. 
Spiekerkoetter E, Tian X, Cai J, Hopper RK, Sudheendra D, Li CG et al (2013). 
FK506 activates BMPR2, rescues endothelial dysfunction, and reverses 
pulmonary hypertension. J Clin Invest 123:3600-3613. 
Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF (2009). Animal models 
of pulmonary arterial hypertension: the hope for etiological discovery and 
pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297:L1013-32. 
Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H et al (2002). 
Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates 
cardiac contractility. Circ Res 91:434-440. 
Wilson DW, Segall HJ, Pan LC, Lamé MW, Estep JE, Morin D (1992).  
Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 
22:307–325. 
34 
 
Violin JD, Lefkowitz RJ (2007). Beta-arrestin-biased ligands at seven-
transmembrane receptors. Trends Pharmacol Sci 28:416-422. 
Viscusi ER, Webster L, Kuss M, Daniels S, Bolognese JA, Zuckerman S et al 
(2016). A randomized, phase 2 study investigating TRV130, a biased ligand of 
the mu-opioid receptor, for the intravenous treatment of acute pain. Pain 
157:264-272. 
Yang P, Maguire JJ, Davenport AP (2015). Apelin, Elabela/Toddler, and biased 
agonists as novel therapeutic agents in the cardiovascular system. Trends 
Pharmacol Sci 36:560-567. 
Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R et al (2017a). 
Elabela/toddler is an endogenous agonist of the apelin APJ receptor in the adult 
cardiovascular system, and exogenous administration of the peptide 
compensates for the downregulation of its expression in pulmonary arterial 
hypertension. Circulation 135:1160-1173. 
Yang P, Kuc RE, Brame AL, Dyson A, Singer M, Glen RC et al (2017). 
[Pyr1]Apelin-13(1-12) is a biologically active ACE2 metabolite of the endogenous 
cardiovascular peptide [Pyr1]Apelin-13. Front Neurosci 11:92. 
Yang X, Zhu W, Zhang P, Chen K, Zhao L, Li J et al (2014). Apelin-13 stimulates 
angiogenesis by promoting cross‑talk between AMP-activated protein kinase and 
Akt signaling in myocardial microvascular endothelial cells. Mol Med Rep 9:1590-
1596. 
Zhao YD, Courtman DW, Ng DS, Robb MJ, Deng YP, Trogadis J et al (2006). 
Microvascular regeneration in established pulmonary hypertension by angiogenic 
gene transfer. Am J Respir Cell Mol Biol 35:182–189. 
  
35 
 
Table 1. MM07 attenuated MCT-induced changes in RVSP, RV hypertrophy and 
pulmonary vascular remodelling 
 
 MCT MCT+MM07 MM07 Control 
n number 8 8 6 6 
Body weight (g) 303±8 295±4 343±9 343±2 
RVSP (mmHg) 50.6±5.9 † 28.2±2.2 ‡ 22.9±1.7 21.9±1.9 
Systolic pressure (mmHg) 105.5±2.0 105.2±1.2 108.2±3.7 104.5±1.6 
Diastolic pressure (mmHg) 76.5±2.5 76.4±0.9 77.0±2.0 77.3±1.2 
Heart rate (bpm) 363±6 365±7 368±15 361±15 
RV weight (g) 0.27±0.02 0.23±0.02 0.16±0.01 0.16±0.01 
LV+S weight (g) 0.67±0.02 0.70±0.02 0.71±0.02 0.74±0.01 
RV/(LV+S) 0.40±0.02 † 0.33±0.03 †‡ 0.22±0.02 0.21±0.01 
Fully muscularised vessels 32±1% † 24±2% †‡ 15±1% 14±1% 
Vessel wall thickness 21±1% † 16±1% †‡ 10±1% 10±1% 
 
† Significantly different versus saline control, ‡ significantly different versus MCT-
exposed rats, as determined by one-way ANOVA with Tukey’s post-test. Data are 
expressed as mean±sem.  P≤0.05 is considered statistically significant. 
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Figure Legends 
Figure 1: (A) Amino acid sequences of MM07 aligned with the sequence of the 
endogenous agonist [Pyr1]apelin-13. Disulphide bridge is shown as yellow lines, 
hydrophobic amino acids shown in green, uncharged polar amino acids in pink, basic 
amino acids in blue with pyroglutamate in red. (B) Experimental design of the MM07-
MCT study. Rats were given MCT (60 mg kg-1) or vehicle on day 0 and daily 
injections of MM07 (1 mg kg-1) or vehicle from day 1 to day 20. Cardiac MRI was 
conducted on day 20 and closed-chest catheterisation was performed on day 21. 
The animals were then euthanized to tissue collection. BW, body weight; sc, 
subcutaneous; ip, intraperitoneal. 
 
Figure 2: MRI of rat hearts in the MM07-MCT study. Representative snapshots of 
cardiac MRI scans at end-systolic, early diastolic and end-diastolic points from MCT, 
MCT+MM07, MM07 and saline injected rats. (A) Short axis views with the RV on the 
left side. (B) Long axis views with the RV at the bottom side. Red arrows are drawn to 
show the point of septal wall bowing at early diastole. 
 
Figure 3: Quantitative analysis of cardiac MRI. (A) MM07 attenuated MCT-induced 
increase in RV end-diastolic volume.  (B) MM07 attenuated MCT-induced increase in 
RV end-systolic volume.  (C) MM07 attenuated MCT-induced decrease in RV ejection 
fraction.  (D) MM07 attenuated MCT-induced decrease in LV end-diastolic volume.  
(E) MCT and MM07 did not alter LV end-systolic volume.  (F) MCT and MM07 did not 
alter LV ejection fraction.  (MCT n=7, MCT-MM07 n=8, MM07 n=4, saline n=4).  
*P≤0.05, determined by Student’s two-tailed t-test.  Data are expressed as 
mean±sem.  EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection 
fraction. 
 
Figure 4: Attenuation of MCT-induced PAH by MM07 administration.  (A) MM07 
attenuated MCT-induced elevation in RVSP.  (B) MM07 attenuated MCT-induced RV 
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hypertrophy, measured as RV/(LV+S), or Fulton index (MCT n=8, MCT-MM07 n=8, 
MM07 n=6, saline n=6).  *P≤0.05, ns not significant, as determined by one-way 
ANOVA with Tukey’s post-test.  Data are expressed as mean±sem. 
 
Figure 5: Immunohistological visualization of remodelling of pulmonary arterioles, 
shown as a vessel close to a terminal bronchiole, using α-smooth muscle actin (brown 
colour A-D) and van Gieson’s stain (E-H) in sections of lung from (A, E) MCT, (B, F) 
MCT+MM07, (C, G) MM07 and (D, H) saline control rats (scale bars=75μm). 
 
Figure 6: Attenuation of MCT-induced pulmonary vascular remodelling by MM07 
administration (MCT n=5, MCT-MM07 n=6, MM07 n=4, saline n=4), measured as (A) 
proportion of muscularised vessels in rat lung and (B) wall thickness of larger, fully 
muscularised pulmonary arterioles.  For (A), statistical significance was assessed by 
comparing the percentage of fully muscularised vessels between groups.  For MCT 
treated animals, comparison of the effect of MM07 and saline was determined by 
Student’s two-tailed t-test, *P≤0.05.  Data are expressed as mean±sem. 
 
Figure 7: MM07 activated endothelial nitric oxide synthase and AMP-activated 
protein kinase.  (A) Stimulation of human PAECs with [Pyr1]apelin-13 or MM07 
increased the level of phosphorylated eNOS measured by chemiluminescence (n=11 
each).  (B) Stimulation of human PAECs with [Pyr1]apelin-13 or MM07 increased the 
level of phosphorylated AMPKa measured by chemiluminescence (n=11 each). RLU, 
relative light units.  *P≤0.05, as determined by repeated measures ANOVA with 
Dunnett’s post-test.  (C), Stimulation of human PAECs with [Pyr1]apelin-13 or MM07 
increased the level of mRNA of eNOS, as determined by one-way ANOVA with 
Tukey’s post-test.  Data are expressed as mean±sem. 
 
Figure 8: MM07 promoted proliferation of pulmonary arterial endothelial cells.  (A) 
Representative two-channel overlay photomicrographs of cells treated with PBS 
(baseline), rhVEGF (as a positive control), [Pyr1]apelin-13 or MM07, showing EdU 
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negative cell nuclei in blue and EdU positive nuclei in cyan.  Scale bar = 200μm.  
(B) Stimulation of human PAECs with rhVEGF, [Pyr1]apelin-13 or MM07 increased 
the proportion EdU positive cells (n=6 each).  *P≤0.05, as determined by a repeated 
measures ANOVA.  Data are expressed as mean±sem. 
 
Figure 9: Rescue of apoptosis of human pulmonary arterial endothelial cells induced 
by TNFα/CHX (n=8 independent experiments using cells from three donors). 
TNFα/CHX significantly induced apoptosis relative to the EBM-2 2%FBS serum and 
growth factor starved control (#p<0.05).  rhVEGF pre-treatment for 18 hours 
significantly attenuated this apoptotic induction as did MM07. *P≤0.05, as determined 
by a repeated measures ANOVA. Data are expressed as mean±sem. 
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